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S U M M A R Y
Objective: To retrospectively investigate the outcomes of patients with AIDS-associated Kaposi sarcoma
(AIDS-KS) after initiation of antiretroviral therapy (ART), under routine practice conditions, at a
university-afﬁliated hospital in urban Zimbabwe.
Background: While studies from developed nations have demonstrated excellent outcomes for AIDS-KS
patients treated with ART, few studies have examined the outcomes of African AIDS-KS patients after
starting therapy.
Methods: A retrospective cohort of 124 AIDS patients initiating ART under routine practice conditions
was studied. Thirty-one patients with AIDS-KS were matched 1:3 to 93 AIDS patients without KS (non-
KS). The primary outcome was loss-to-care after initiation of therapy. Multivariate analysis was
performed to identify signiﬁcant predictors of loss-to-care. The percent change in weight at 6 months
after starting ART was a secondary outcome. A sub-group analysis evaluated differences in pre-
treatment variables between AIDS-KS patients retained-in-care compared to those lost-to-care.
Results: AIDS-KS patients had signiﬁcantly greater 2-year proportional loss-to-care than matched non-
KS AIDS patients (26.4% vs. 9.5%; p = 0.01) after initiation of ART. In multivariate analysis, the presence of
KS (p = 0.02) was the only signiﬁcant predictor of loss-to-care. AIDS-KS patients had signiﬁcantly less
weight gain after starting ART than non-KS AIDS patients (+3.4% vs. +6.4%; p = 0.03). AIDS-KS patients
retained-in-care had signiﬁcantly higher pre-treatment CD4+ lymphocyte counts than AIDS-KS patients
lost-to-care (223 vs. 110 cells/mm3; p = 0.04).
Conclusions: In this retrospective study, AIDS-KS patients experienced signiﬁcantly worse outcomes
than matched non-KS AIDS patients after initiation of ART. AIDS-KS patients with higher pre-treatment
CD4+ lymphocyte counts were more likely to be retained in care.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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AIDS-associated Kaposi sarcoma (AIDS-KS) results from co-
infection with HIV-1 and Kaposi sarcoma-associated herpes virus
(KSHV) and it is the most common AIDS-related malignancy
worldwide.1–4 The high prevalence of HIV-1/KSHV co-infection in§ Presented in part at the 12th International Conference on Malignancy in AIDS
and Other Acquired Immunodeﬁciencies.
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http://dx.doi.org/10.1016/j.ijid.2013.04.011Sub-Saharan Africa places 30–50% of HIV-1-infected individuals
from this region at risk for development of AIDS-KS.5–10 The
introduction of multi-drug antiretroviral therapy (ART) regimens
in developed countries has been associated with a signiﬁcant
decrease in the incidence of AIDS-KS11 as well as improved patient
survival. Studies from North American and European cohorts have
demonstrated signiﬁcant tumor regression and 5-year AIDS-KS
survival rates near 90% after initiation of ART in early-stage
disease.12–15 However, similar outcome data for AIDS-KS patients
from Sub-Saharan African populations, where AIDS-KS remains a
signiﬁcant cause of morbidity and mortality resulting in 10–14% of
deaths in ART programs,16,17 are lacking. Several recent ARTses. Published by Elsevier Ltd. All rights reserved.
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improvements in outcomes as those reported in studies from
developed nations.18–20
Due to co-morbid conditions, limited access to antiretroviral
medications, initiation of treatment at later disease stage, and,
potentially, different host and viral genetic factors, the response of
AIDS-KS patients to ART in Sub-Saharan Africa may be different
than that reported in developed countries. In order to improve the
treatment of AIDS-KS in African settings, it is necessary to better
understand if and how AIDS-KS may lead to worse ART outcomes.
The objective of the present study was to improve that
understanding by investigating the outcomes of AIDS-KS patients
after initiation of ART at a university-afﬁliated hospital in urban
Zimbabwe, as well as the factors associated with those outcomes.
2. Methods
2.1. Study subjects
This study followed the US Department of Health and Human
Services guidelines for human experimentation and was approved
by the Colorado Multiple Institutional Review Board, the Joint
Parirenyatwa Hospital College of Health Sciences Research Ethics
Committee, and the Medical Research Council of Zimbabwe. The
study was conducted by retrospective review of medical records
from the Parirenyatwa Hospital Kaposi Sarcoma Clinic and the
Family Care Centre (also known as the Opportunistic Infections/
ART Clinic) in Harare, Zimbabwe. At that time, the Family Care
Centre provided ART for patients with: CD4+ lymphocyte count
<250 cells/mm3, history of World Health Organization (WHO) HIV
stage 3 or 4 disease, current pregnancy, or current use of ART at
enrolment. All patients received an intake assessment where
available pre-treatment demographic and clinical data were
recorded. Clinical assessment included determination of AIDS
Clinical Trials Group (ACTG) KS disease stage21,22 for AIDS-KS
patients. Pre-treatment laboratory data typically included HIV
serology, CD4+ lymphocyte count, complete blood count, basic
metabolic panel, and liver function testing; however, complete
baseline laboratory tests were not obtained in all cases. The
standard initial ART regimen was stavudine, lamivudine, and
nevirapine. Patients receiving concomitant treatment for tubercu-
losis had efavirenz substituted for nevirapine. Patients typically
received antiretroviral medications in 1-month allotments and
were required to reﬁll prescriptions at the Family Care Centre
pharmacy monthly.
All AIDS-KS patients enrolled in the Kaposi Sarcoma Clinic at
Parirenyatwa Hospital, receiving ART through the Family Care
Centre during the study enrolment period (January 1, 2004 to
November 1, 2006), were screened for inclusion. Patients with less
than 6 months of follow-up in the Kaposi Sarcoma Clinic and/or the
Family Care Centre, or documented transfer of care to another
facility, were excluded from the study to minimize inclusion of
patients not committed to care through these clinics. Patients who
had received more than 2 months of previous ART prior to
enrolment at the Family Care Centre were also excluded. Included
AIDS-KS patients were matched 1:3 to HIV-positive patients
meeting a diagnosis of AIDS based on a CD4+ lymphocyte count
<250 cells/mm3, or WHO HIV stage 4 disease, without known KS
(non-KS), also receiving ART through the Family Care Centre.
Matching was based on gender, date of initiation of ART, and age.
All patients were gender-matched exactly. Non-KS AIDS patients of
the appropriate gender who had initiated ART within 2 months of
the date an AIDS-KS patient had started treatment were then
identiﬁed. Of these identiﬁed patients, the non-KS AIDS patient
closest in age to the AIDS-KS patient being matched was
subsequently included in the study. Patients were matched forgender and age because Zimbabwean AIDS-KS patients are more
often male and have an older age distribution than non-KS AIDS
patients.23,24 Pregnancy was not accounted for in matching, as few
(n = 5) gravid patients were included.
2.2. Statistical analysis
The primary outcome was loss-to-care, deﬁned as failure to
attend clinic or reﬁll prescriptions for 3 months or longer during
the study period. Loss-to-care was conﬁrmed by follow-up review
of the available medical records after study termination. Loss-to-
care was used as the primary outcome because patient deaths were
not accurately recorded in Zimbabwe at the time of the study and
available data suggest that in African settings, loss-to-care for
more than 3 months is associated with clinically relevant
outcomes including severe debilitation and death.25,26 Loss-to-
care was analyzed by standard univariate Kaplan–Meier method-
ology with termination of the study (August 1, 2007) as a censoring
event. A two-step model-selection strategy was used to identify
independent predictors of loss-to-care. Pre-treatment variables
included in an initial screening univariate Cox proportional
hazards regression analysis were: presence of KS, gender, age,
marital/partner status (married/partner vs. no partner), having
private medical aid (yes vs. no or not reported), employment status
(full- or part-time employment vs. unemployed, self-employed or
not reported), education level (O level education or higher vs.
secondary education or less), housing type (own or rent vs. living
with family or homeless), WHO performance status (1 vs. >1), pre-
treatment CD4+ lymphocyte count (<50 vs. 50 cells/mm3), pre-
treatment hemoglobin (g/dl), and pre-treatment albumin (g/dl). A
ﬁnal multivariate Cox proportional hazards regression analysis
was performed on all variables with p < 0.15 in the initial
univariate analysis, with statistical signiﬁcance deﬁned as p < 0.05.
The percent change in weight at 6 months after initiation of ART
was a secondary outcome. The absolute change in CD4+ lympho-
cyte count and the total CD4+ lymphocyte count within 1 year of
initiating ART were also deﬁned secondary outcomes; however,
only ﬁve AIDS-KS patients and 46 non-KS AIDS patients had follow-
up CD4+ cell counts recorded and therefore assessment of these
outcomes was underpowered to detect a signiﬁcant difference.
Secondary outcome variables were non-parametrically distributed
and were analyzed using the Mann–Whitney rank sum test. A
subgroup analysis was performed comparing the pre-treatment
variables of AIDS-KS patients retained-in-care to those AIDS-KS
patients lost-to-care. Pre-treatment demographic and clinical
variables were analyzed by Fisher’s exact test for categorical
variables and Student’s t-test for continuous variables. Statistical
signiﬁcance was deﬁned as p < 0.05 and all applicable tests were
two-tailed.
3. Results
The medical records of 110 AIDS-KS patients were reviewed and
31 met criteria for inclusion. Reasons for exclusion were: no or
unknown initiation date of ART (n = 34), less than 6 months follow-
up (n = 28), and receiving more than 2 months of ART prior to
enrolment at the Family Care Centre (n = 17). Ninety-three non-KS
AIDS patients were matched for inclusion from a pool of 426
screened patients. Of the 426 screened patients, 288 did not meet
criteria for inclusion based on: no or unknown initiation date of
ART (n = 118), less than 6 months follow-up (n = 43), receiving
more than 2 months of ART prior to enrolment at the Family Care
Centre (n = 123), documented transfer of care to another facility
(n = 3), and unknown age (n = 1). Forty-ﬁve patients met criteria for
inclusion but were not included due to being an inferior match.
AIDS-KS and non-KS AIDS patients were matched exactly by
Figure 1. Two-year Kaplan–Meier plot for time to loss-to-care after initiation of
antiretroviral therapy. Time 0 was deﬁned as the ﬁrst ﬁlled antiretroviral
prescription date. Time at loss-to-care was deﬁned as the last attended clinic
date or prescription reﬁll date, with loss-to-care reﬂecting failure to follow up in
clinic or reﬁll prescriptions for more than 3 months from that date. p = 0.01 for the
analysis.
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1.7 days and age of 0.3 years between AIDS-KS and non-KS AIDS
patients within matched sets (Supplementary Material, Table S1).
The overall study population had a mean age of 38 years, with 52%
female subjects. Pre-treatment demographic and clinical variables
were not signiﬁcantly different between the study groups except
for CD4+ lymphocyte count and non-KS WHO HIV disease stage.
AIDS-KS patients had a signiﬁcantly higher mean pre-treatment
CD4+ lymphocyte count (195 vs. 92 cells/mm3; p = 0.006) and were
less likely to have non-KS WHO HIV stage 3 or 4 disease (34.8% vs.
94.1%; p < 0.001) than matched non-KS AIDS patients (Table 1).
Amongst AIDS-KS patients, 9.7% were ACTG KS stage T0S0, 35.5%
stage T1S0, 9.7% stage T0S1, and 45.2% stage T1S1.
For the complete study cohort, initial ART regimens were
stavudine, lamivudine, and nevirapine (96%) and stavudine,
lamivudine, and efavirenz (4%). All AIDS-KS patients received
stavudine, lamivudine, and nevirapine as their initial ART regimen.
Two AIDS-KS patients (6.5%) were changed from stavudine,
lamivudine, and nevirapine to an alternate regimen during the
study period. Five non-KS AIDS patients (5.4%) started treatment
with stavudine, lamivudine, and efavirenz and eight (8.6%) were
changed from stavudine, lamivudine, and nevirapine to an
alternate regimen during the study period.
Two-year proportional loss-to-care was 26.4% for AIDS-KS
patients (8 of 31) and 9.5% (8 of 93) for non-KS AIDS patients (p =
0.01; hazard ratio (HR) 3.35, 95% conﬁdence interval (CI) 1.05–
10.75; Figure 1). In the initial univariate screening analysis, the
presence of KS, age, marital/partner status, and housing type met
criteria for inclusion in the ﬁnal multivariate analysis (Table 2). In
the multivariate analysis, only the presence of KS (p = 0.02; HR
3.83, 95% CI 1.25–11.73) was found to be a signiﬁcant predictor of
loss-to-care (Table 3).Table 1
Comparison of overall pre-treatment variables for AIDS-KS vs. non-KS AIDS patients
Pre-treatment variable AIDS-KS
Mean or % (n)
Non-KS AIDS
Mean or % (n)
p-Value
Age (years) 38.4 (31) 38.2 (93) 0.86
Gender
Male 48.4 (15) 48.4 (45)
Female 51.6 (16) 51.6 (48) 1
Private medical aid
No or not reported 71.0 (22) 77.4 (72)
Yes 29.0 (9) 22.6 (21) 0.63
Marital/partner status
No partner 64.5 (20) 55.9 (52)
Married/partner 43.5 (11) 44.1 (41) 0.53
Education
Secondary or less 38.5 (10) 44.8 (39)
O level or higher 62.5 (16) 55.2 (48) 0.65
Employment
Self- or unemployed
or not reported
67.7 (21) 72.0 (67)
Part- or full-time employment 32.3 (10) 28.0 (26) 0.82
Housing type
With family or homeless 47.8 (11) 40.5 (34)
Own or rent 52.2 (12) 59.5 (50) 0.63
Co-trimoxazole use
Yes 93.5 (29) 90.6 (77)
No 6.5 (2) 9.4 (8) 0.73
WHO performance status
1 52.6 (10) 49.0 (24)
>1 47.4 (9) 51.0 (25) 1
Non-KS WHO HIV disease stage
1–2 65.2 (15) 5.7 (5)
3–4 34.8 (8) 94.3 (82) <0.001
Hemoglobin (g/dl) 11.7 (29) 11.3 (87) 0.34
Albumin (g/dl) 3.46 (18) 3.48 (57) 0.93
Weight (kg) 61.7 (26) 58.3 (86) 0.13
CD4+ cell count (cells/mm3) 195 (28) 92 (92) 0.01
KS, Kaposi sarcoma; WHO, World Health Organization.AIDS-KS patients had signiﬁcantly less median weight gain at 6
months after initiation of ART than non-KS AIDS patients (+3.4% vs.
+6.4%; p = 0.03). While there were no signiﬁcant differences
between AIDS-KS and non-KS AIDS patients for median change in
CD4+ lymphocyte count (71 vs. 148 cells/mm3; p = 0.18) or total
CD4+ lymphocyte count (243 vs. 236 cells/mm3; p = 0.78) within 1
year of starting ART, as described previously, these analyses were
underpowered to detect a signiﬁcant difference.
AIDS-KS patients lost-to-care had a signiﬁcantly lower mean
pre-treatment CD4+ lymphocyte count than AIDS-KS patients
retained-in-care (110 vs. 223 cells/mm3; p = 0.04). No other
statistically signiﬁcant differences in pre-treatment variables were
found between AIDS-KS patients lost-to-care compared to those
retained-in-care (Supplementary Material, Table S2).
4. Discussion
AIDS-KS patients initiating ART as part of routine clinical care at
a university-afﬁliated hospital in urban Zimbabwe had a high rate
of a poor clinical outcome (26.4% 2-year proportional loss-to-care).
Compared to matched AIDS patients without KS, AIDS-KS patients
at our study site had more than three times the risk of loss-to-care
and worse weight gain after starting therapy. These ﬁndings
contrast with much of the recent literature from European and
American study populations, which has generally reported
excellent outcomes in AIDS-KS patients treated with ART.12–15
While it is important to recognize that many of the studied cohortsTable 2
Univariate Cox proportional hazards regression analysis for pre-treatment variables
Pre-treatment variable Covariate predictive of loss-to-care p-Value
KS status AIDS-KS 0.02
Age Per year increasea 0.13
Gender Female 0.42
Marital/partner status No partner 0.10
Private medical aid Yes 0.53
Employment Self- or unemployed or not reported 0.33
Education Secondary or less 0.29
Housing type With family or homeless 0.05
WHO performance status 1 0.48
CD4+ cell count (cells/mm3) CD4+ cell count <50 0.50
Hemoglobin (g/dl) Per unit decreasea 0.51
Albumin (g/dl) Per unit decreasea 0.32
KS, Kaposi sarcoma; WHO, World Health Organization.
a Indicates continuous variable.
Table 3
Multivariate Cox proportional hazards regression analysis for qualifying pre-
treatment variables (p < 0.15 in univariate analysis)
Covariate predictive of loss-to-care HR 95% CI p-Value
AIDS-KS 3.83 1.25–11.73 0.02
Age per yeara 0.97 0.90–1.05 0.44
No partner 2.48 0.59–10.42 0.21
Living with family or homeless 1.70 0.39–7.37 0.48
HR, hazard ratio; CI, conﬁdence interval; KS, Kaposi sarcoma.
a Indicates continuous variable.
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stage AIDS-KS subjects than our study, in which most subjects had
ACTG stage T1 and/or S1 disease, these results nonetheless suggest
a disparate response to ART in Zimbabwean AIDS-KS patients.
Aside from the presence of KS disease, reasons for the increased
rate of loss-to-care among AIDS-KS patients in our study were not
evident. Available measures of functional capacity, education, and
economic status were not signiﬁcantly different between the KS
and non-KS groups. Furthermore, while advanced HIV disease
stage and markers of malnutrition are associated with increased
mortality risk in African ART programs,21–23 in this study the
increased risk of poor outcome in AIDS-KS patients could not be
attributed to pre-treatment HIV-1-related immunosuppression,
malnutrition, or concomitant opportunistic infections. Compared
to matched non-KS AIDS patients, AIDS-KS patients had signiﬁ-
cantly higher pre-treatment CD4+ lymphocyte counts, lower
frequency of non-KS WHO HIV stage 3 or 4 disease, and similar
hemoglobin and albumin levels prior to initiation of ART.
Additionally, our multivariate analysis identiﬁed the presence of
KS as the only independent predictor of loss-to-care, indicating
that KS independently and adversely affected the outcomes of
AIDS-KS patients during ART treatment separate from other pre-
treatment clinical and demographic factors.
Overall, our study suggests that Zimbabwean AIDS-KS patients
have a poorer response to ART than what has been reported in
European and American patients. While this study was not
designed to elucidate the reasons for this disparity, potential
explanations include the use of different antiretroviral agents,
initiation of treatment at an earlier KS disease stage, superior pre-
treatment clinical status, fewer co-morbid conditions, more robust
societal and economic support systems, and different viral and
host genetic factors in Western populations. In order to improve
the outcomes of AIDS-KS patients in Sub-Saharan Africa, further
basic science and prospective studies are warranted to investigate
these possible explanations. Our results did show that AIDS-KS
patients retained-in-care had signiﬁcantly higher pre-treatment
CD4+ lymphocyte counts than those patients lost-to-care, a ﬁnding
that supports early initiation of ART as one effort to improve AIDS-
KS outcomes.
Our study has several limitations. This was an urban,
university-afﬁliated, single-center study using older generation
antiretroviral agents, which potentially limits the generalizability
of our results to other African and non-African populations. This
problem may be ameliorated by the fact that we studied subjects
receiving routine care and not subjects enrolled in clinical trials, a
cohort that more accurately reﬂects the treatment most African
AIDS-KS patients receive. The retrospective design of the study
restricted our analyses only to information that was recorded as
part of routine care at Parirenyatwa Hospital and, while previous
studies have shown that patients lost-to-care experience poor
outcomes, we were unable to directly assess the clinical
consequences of loss-to-care. The inclusion criteria also likely
resulted in the exclusion of those AIDS-KS patients at the greatest
risk for poor outcomes, including patients who never initiated ARTor were lost-to-care less than 6 months after starting ART. Since
these patients were a large portion (56.4%) of all AIDS-KS patients
who received ART through the Family Care Centre, it is possible
that we have underestimated the overall risk of poor outcome
during treatment of AIDS-KS in urban Zimbabwe. Additional
prospective studies from larger and more diverse African popula-
tions are needed to address these shortcomings.
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